The Breast
Volume 19, Issue 6 , Pages 545-548 , December 2010

Defining ovarian failure in amenorrheic young breast cancer patients

  • Eitan Amir

      Affiliations

    • Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    • Corresponding Author InformationCorresponding author at: Division of Medical Oncology, Room 5-224, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada. Tel.: +1 416 946 4534; fax: +1 416 946 2983.
    • ,
  • Orit Freedman

      Affiliations

    • Medical Oncology, Durham Regional Cancer Centre, Oshawa, Canada
    • ,
  • Lisa Allen

      Affiliations

    • Department of Gynecology, Mount Sinai Hospital, Toronto, Canada
    • ,
  • Terence Colgan

      Affiliations

    • Department of Pathology, Mount Sinai Hospital, Toronto, Canada
    • ,
  • Mark Clemons

      Affiliations

    • Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Canada

Received 9 November 2009 ,Revised 14 June 2010 ,Accepted 15 June 2010.

References 

  1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC cancerbase No. 5, version 2.0. Lyon: IARCPress; 2004;
  2. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467
  3. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930–942
  4. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 2007;43:1646–1653
  5. Schinzinger A. 18th Congress of the German Society for Surgery. Beilage zum Centralblatt fur Chirurgie. 1889;16:55–56Ueber carcinoma mammae [abstract]
  6. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431–2442
  7. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305–309
  8. Smith IE, Dowsett M, Yap YS, Walsh G, Lønning PE, Santen RJ, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhea: caution and suggested guidelines. J Clin Oncol. 2006;24:2444–2447
  9. Young Survival Coalition . Young women and breast cancer. http://www.youngsurvival.org/young-women-and-bc/[Accessed 09.09.08]
  10. Davidson NE. Adjuvant therapy for premenopausal women with endocrine-responsive disease. ASCO. 2009;
  11. Amir E, Seruga B, Freedman OC, Clemons M. Endocrine therapy for breast cancer: prolonged amenorrhoea is not necessarily indicative of menopause. BMJ. 2009;339:b4261
  12. World Health Organization . Technical report series 670: research on the menopause. Geneva, Switzerland: WHO; 1991;
  13. Wang S, Paris F, Sultan CS, Song RX, Demers LM, Sundaram B, et al. Recombinant cell ultrasensitive bioassay for measurement of estrogens in postmenopausal women. J Clin Endocrinol Metab. 2005;90:1407–1413
  14. Sundaram B, Ohorodnik S, Settlage J, Taylor P. A bioanalytical method for the quantitation of estradiol, estrone, testosterone and dihydrotestosterone in human serum. AAPS PharmSci. 2003;5(S1):
  15. World Health Organization . Report of a WHO Scientific Group Research on the menopause. Geneva: World Health Organization; 1981;WHO Technical Report Series No. 670
  16. Sharara FI, Scott RT. Assessment of ovarian reserve. Is there still a role for ovarian biopsy? First do no harm!. Hum Reprod. 2004;19:470–471
  17. Clemons M, Simmons C. Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Res Treat. 2007;104:115–120
  18. Delrio G, De Placido S, Pagliarulo C, d’Istria M, Fasano S, Marinelli A, et al. Hypothalamic–pituitary–ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. Tumori. 1986;72:53–61
  19. Rossi E, Morabito A, Di Rella F, Esposito G, Gravina A, Labonia V, et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol. 2009 Jul 1;27(19):3192–3197
  20. Lum SS, Woltering EA, Fletcher WS, Pommier RF. Changes in serum estrogen levels in women during tamoxifen therapy. Am J Surg. 1997;173(5):399–402
  21. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006;21:2583–2592
  22. Petrek NA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24:1045–1051
  23. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30:126–132
  24. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: the International Breast Cancer Study Group. Ann Oncol. 1990;1:183–188
  25. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–1729
  26. Nabholtz J, Pienkowski T, Mackey J, Pawlicki M, Guastalla J, Vogel C, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol. 2002;21:36a;[abstr 141]
  27. Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24:5664–5671
  28. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104:1575–1579
  29. Oktay K, Libertella N, Oktem O, Beck L, Cil A. The impact of paclitaxel on menstrual function. Breast Cancer Res Treat. 2005;94:S271;[abstr 6067]
  30. Vital-Reyes V, Tellez-Velasco S, Chhieng D, Grizzle W, Reyes-Fuentes A. Spontaneous pregnancy in a woman with premature ovarian failure: a case report. J Reprod Med. 2004;49:989–991
  31. Smith IE, Dowsett M, Yap YS, Walsh G, Lønning PE, Santen RJ, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 2006;24:2444–2447
  32. Bukulmez O, Arici A. Assessment of ovarian reserve. Curr Opin Obstet Gynecol. 2004;16(3):231–237
  33. Sit AS, Modugno F, Hill LM, Martin J, Weissfeld JL. Transvaginal ultrasound measurement of endometrial thickness as a biomarker for estrogen exposure. Cancer Epidemiol Biomarkers Prev. 2004;13:1459–1465
  34. Sharara FI, Scott RT, Seifer DB. Contemporary investigation of ovarian reserve in infertile women. Am J Obstet Gynecol. 1998;179:804–812
  35. VanRooij IAJ, Broekmans FJM, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–3071
  36. Kwee J, Elting MW, Schats R, Bezemer PD, Lambalk CB, Schoemaker J. Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study. Hum Reprod. 2003;18:1422–1427
  37. Larsen EC, Muller J, Rechnitzer C, Schmiegelow K, Andersen AN. Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH <10 IU/l. Hum Reprod. 2003;18:417–422
  38. Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab. 2003;88:5307–5314
  39. Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C. Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve. Fertil Steril. 2008;90:737–743
  40. van Beek RD, van den Heuvel-Eibrink MM, Laven JS. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin’s lymphoma during childhood. J Clin Endocrinol Metab. 2007;92:3869–3874
  41. Lutchman Singh K, Muttukrishna S, Stein RC, McGarrigle HH, Patel A, Parikh B, et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer. 2007;96:1806–1816

PII: S0960-9776(10)00153-0

doi: 10.1016/j.breast.2010.06.003

The Breast
Volume 19, Issue 6 , Pages 545-548 , December 2010

Article Tools

* Image Usage & Resolution